An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial
Lopes R, Vora A, Liaw D, Granger C, Darius H, Goodman S, Mehran R, Windecker S, Alexander J. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. American Heart Journal 2018, 200: 17-23. PMID: 29898844, DOI: 10.1016/j.ahj.2018.03.001.Peer-Reviewed Original ResearchConceptsAcute coronary syndromePercutaneous coronary interventionAtrial fibrillationOral anticoagulantsCoronary syndromeNon-Vitamin K Antagonist Oral AnticoagulantsRandomized trialsClinically relevant nonmajor bleedingConcomitant coronary artery diseaseCoronary interventionInternational Society on ThrombosisAntithrombotic therapy strategiesEvaluated ischemic outcomesP2Y12 receptor inhibitionOptimal antithrombotic regimenVitamin K antagonistsProspective randomized trialsRisk of bleedingOptimal antithrombotic strategyMulticenter randomized trialRecurrent ischemic eventsComposite of deathGroup of patientsCoronary artery diseaseBenefit of aspirin
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply